PATENT CLAIM ANALYSIS

Application Number: 16221442
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-10
Patent Classification: ["424", "190100"]

Abstract:
The present invention is directed to a monoclonal antibody that binds specifically to a  Staphylococcus aureus  glucosaminidase and inhibits in vivo growth of  S. aureus . Also disclosed are monoclonal antibody binding portions, recombinant or hybridoma cell lines, pharmaceutical compositions containing the monoclonal antibody or binding portions thereof, and methods of treating  S. aureus  infection and osteomyelitis, and methods for introducing an orthopedic implant into a patient using the monoclonal antibody, binding portion, or pharmaceutical composition of the present invention.

Claim (Index 1):
A monoclonal antibody or binding portion thereof that binds specifically to a  Staphylococcus aureus  glucosaminidase and inhibits in vivo growth of  S. aureus.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 98.0
- Lexical Diversity: 1.64151
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15662715', '13696019', '14355524', '15682274', '15283901']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8233719407887513
- 35 USC 102 Novelty (BERT): 0.6127280921115269
- Combined Prediction Score: 0.8023075559210289
- Mean Citation Score: 514.3444420000002
- Max Citation Score: 555.145
- Similarity Product: 515.3077954670787

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test